Role of Medicinal Plants in Hepatoprotective Drug Development

Dr. Wei H Zhang [1*], Dr. Lin Z Liu [2]
[1] State Key Laboratory of Drug Delivery, Fudan University, China
[2] Department of Nanomedicine, Peking University, China

* Corresponding Author: **Dr. Wei H Zhang**

Article Info

ISSN (online): 3049-0421
Volume: 02
Issue: 06
November-December 2025
Received: 22-09-2025
Accepted: 20-10-2025
Published: 18-11-2025
Page No: 58-64

Abstract
Liver diseases constitute a major global health burden, collectively affecting hundreds of millions of individuals and contributing significantly to morbidity and mortality worldwide. Current therapeutic options, including antiviral agents for viral hepatitis and liver transplantation for end-stage disease, remain constrained by high cost, adverse effects, limited availability, and the absence of universally effective pharmacological agents for conditions such as non-alcoholic steatohepatitis (NASH) and drug-induced liver injury (DILI). Against this backdrop, medicinal plants have emerged as promising and historically substantiated sources of hepatoprotective compounds. This review critically examines the role of medicinal plants in hepatoprotective drug development, with particular emphasis on the biochemical mechanisms underlying their therapeutic actions. Key mechanisms explored include antioxidant reinforcement of the glutathione system, suppression of pro-inflammatory cytokines, modulation of hepatic detoxification enzymes such as cytochrome P450 isoforms, and prevention of fibrogenic activation of hepatic stellate cells. Bioactive constituents including flavonoids, polyphenols, alkaloids, and terpenoids are discussed in the context of their pharmacological profiles and mechanistic relevance. The review further evaluates preclinical evidence from *in vitro* and *in vivo* studies, highlights challenges in clinical translation including pharmacokinetic variability and lack of standardized extract formulations, and addresses emerging strategies in novel drug delivery systems. Regulatory and commercialization hurdles are examined critically. The manuscript concludes by delineating future research priorities aimed at bridging the gap between experimental findings and clinical hepatoprotective therapies derived from plant-based sources.

Keywords: Medicinal plants, Hepatoprotection, Liver diseases, Phytochemicals, Drug development, Translational research

1. Introduction

Liver disease represents one of the foremost public health challenges of the contemporary era. The liver, by virtue of its central role in metabolism, detoxification, protein synthesis, and bile production, is uniquely susceptible to a wide range of endogenous and exogenous insults [1]. Globally, chronic liver diseases, including cirrhosis, viral hepatitis B and C, alcoholic liver disease (ALD), and non-alcoholic fatty liver disease (NAFLD), affect an estimated 844 million individuals, with mortality from cirrhosis alone surpassing one million deaths annually [2]. In addition to chronic conditions, acute liver failure and drug-induced hepatotoxicity constitute life-threatening emergencies with limited pharmacological recourse [3].

Despite decades of pharmaceutical research, the therapeutic landscape for liver disease remains inadequately populated. Approved pharmacological agents are largely restricted to direct-acting antivirals for hepatitis B and C, corticosteroids with limited utility in autoimmune hepatitis, and ursodeoxycholic acid for primary biliary cholangitis [4]. No pharmacological agent has received regulatory approval for NASH, which is projected to become the leading indication for liver transplantation in the near future [5]. The absence of effective hepatoprotective drugs with broad mechanistic coverage has reinvigorated scientific

interest in medicinal plants as alternative or complementary therapeutic sources [6].

Ethnopharmacology and traditional medicine systems, including Ayurveda, Traditional Chinese Medicine (TCM), and Unani, have long documented the hepatoprotective properties of numerous botanical species [7]. The global medicinal plant market continues to expand, reflecting both public demand and growing evidence of phytochemical efficacy. Modern pharmacological research has begun to validate many traditional hepatoprotective claims through rigorous *in vitro*, *in vivo*, and limited clinical investigations [8]. This review synthesizes current knowledge on the mechanisms, translational challenges, and drug development potential of medicinal plants for liver disease, with a focus on fostering evidence-based integration into therapeutic pipelines [9].

2. Pathophysiology of Liver Injury

An understanding of the molecular and cellular mechanisms underlying hepatic injury is prerequisite to appreciating the pharmacological targets of plant-derived hepatoprotective agents. Liver injury may be initiated by diverse insults, yet the downstream pathological mechanisms exhibit substantial convergence across etiologies [10]. Oxidative stress, inflammatory signaling, mitochondrial dysfunction, and hepatic stellate cell activation constitute the cardinal pathological axes.

Oxidative stress is initiated when the generation of reactive oxygen species (ROS) and reactive nitrogen species (RNS) exceeds the antioxidant capacity of the hepatocyte. Excess ROS cause lipid peroxidation of cellular membranes, oxidative modification of proteins, and DNA strand breaks, collectively impairing hepatocellular integrity [11]. The Nrf2-Keap1 pathway serves as a master regulator of antioxidant gene expression; its dysregulation is a hallmark of multiple liver disease phenotypes [12]. Concurrently, mitochondrial dysfunction amplifies ROS generation and promotes cytochrome c release, initiating intrinsic apoptotic cascades in hepatocytes.

Inflammatory mechanisms are orchestrated principally through activation of Kupffer cells, the resident macrophages of the liver, which upon stimulation release tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1beta), and interleukin-6 (IL-6) [13]. These cytokines perpetuate hepatocyte injury through NF-kappaB-dependent transcriptional programs, inducing adhesion molecules and recruiting circulating immune cells to the hepatic parenchyma. Prolonged inflammation drives the activation of hepatic stellate cells (HSCs), which undergo myofibroblastic transformation and secrete extracellular matrix proteins, principally collagen type I, leading to progressive fibrosis and ultimately cirrhosis [14]. The TGF-beta1/Smad pathway is central to HSC activation and represents an important anti-fibrotic target for therapeutic intervention [15].

3. Medicinal Plants and Their Bioactive Constituents

The pharmacopoeia of hepatoprotective medicinal plants encompasses several thousand species distributed across tropical, subtropical, and temperate regions. The most extensively investigated include Silybum marianum (milk thistle), Andrographis paniculata, Phyllanthus niruri, Curcuma longa, Glycyrrhiza glabra, and Picrorhiza kurroa, among others [16]. These plants harbor structurally diverse bioactive constituents that confer their hepatoprotective pharmacological activities.

Flavonoids constitute one of the most pharmacologically active phytochemical classes with documented hepatoprotective activity. Silymarin, a standardized flavonolignan complex derived from Silybum marianum, remains the most widely studied hepatoprotective natural product globally. Its principal constituent, silybin, exhibits antioxidant, anti-inflammatory, and antifibrotic properties with a well-characterized mechanistic profile [17]. Other flavonoids of hepatoprotective relevance include quercetin, kaempferol, and naringenin, which modulate oxidative signaling, mitochondrial biogenesis, and hepatocyte apoptosis.

Polyphenols, including curcumin from Curcuma longa and resveratrol from Vitis vinifera, exert pleiotropic hepatoprotective effects through modulation of NF-kappaB, Nrf2, and SIRT1 pathways [18]. Curcumin, in particular, has demonstrated efficacy across multiple experimental models of hepatic injury, though its clinical translation has been impeded by poor bioavailability owing to rapid metabolic conjugation and low systemic absorption. Terpenoids, including andrographolide from Andrographis paniculata, glycyrrhizin from Glycyrrhiza glabra, and picroside I from Picrorhiza kurroa, modulate hepatic immune responses and detoxification enzyme activity [19]. Alkaloids such as berberine from Berberis vulgaris have demonstrated significant hepatoprotective and lipid-lowering effects through AMPK activation, positioning them as candidates for NAFLD pharmacotherapy [20].

4. Mechanisms of Hepatoprotective Action

The hepatoprotective mechanisms of medicinal plant constituents are mechanistically diverse and frequently synergistic, operating across complementary molecular targets. Antioxidant defense enhancement constitutes the most consistently documented mechanism. Flavonoids and polyphenols augment the activity of superoxide dismutase (SOD), catalase, and glutathione peroxidase, while upregulating glutathione synthesis through Nrf2-mediated transcriptional activation of gamma-glutamylcysteine synthetase [21]. Direct free radical scavenging by phenolic hydroxyl groups contributes additional antioxidant capacity, particularly relevant under conditions of acute hepatotoxic insult.

Anti-inflammatory mechanisms are central to the hepatoprotective effects of numerous plant compounds. Andrographolide, glycyrrhizin, and silybin each suppress NF-kappaB activation through distinct upstream mechanisms, resulting in attenuated transcription of pro-inflammatory cytokines and chemokines [22]. Inhibition of arachidonic acid metabolism, including suppression of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX), further limits prostaglandin and leukotriene-mediated hepatic inflammation. These anti-inflammatory actions are particularly relevant in the context of alcoholic hepatitis and NASH, where inflammatory cascades are predominant pathogenic drivers.

Modulation of hepatic detoxification enzyme systems represents a pharmacologically important mechanism. Cytochrome P450 (CYP450) enzymes, particularly CYP2E1, generate toxic metabolic intermediates including reactive electrophiles under conditions of ethanol exposure and

xenobiotic challenge [23]. Several plant extracts and isolated compounds, including catechins from Camellia sinensis, demonstrate CYP2E1 inhibitory activity while simultaneously inducing phase II conjugation enzymes such as glutathione S-transferase (GST) and UDP-glucuronosyltransferase (UGT), thereby shifting hepatic metabolism toward detoxification. Antifibrotic mechanisms involve inhibition of TGF-beta1-induced HSC activation and collagen synthesis. Silybin, berberine, and piperine have each demonstrated capacity to attenuate HSC myofibroblastic transformation and reduce hepatic collagen deposition in experimental fibrosis models [24].

5. Preclinical and Translational Research

The preclinical evidence base for hepatoprotective medicinal plants spans a spectrum of *in vitro* and *in vivo* experimental methodologies. Cell-based studies employing hepatocyte cell lines, including HepG2, HepaRG, and primary hepatocytes, have been used to characterize cytoprotective activity against chemical hepatotoxins such as carbon tetrachloride (CCl4), acetaminophen (APAP), and thioacetamide [25]. These models permit rapid screening of extract activity and mechanistic interrogation but are limited by their inability to recapitulate the complex hepatic microenvironment.

Rodent models of hepatic injury, including CCl4-induced fibrosis, bile duct ligation, high-fat diet-induced NAFLD, and lipopolysaccharide/galactosamine-induced acute liver failure, have been extensively employed for *in vivo* evaluation of plant extracts [26]. Standardized hepatotoxicity markers, including serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and histopathological liver scoring, provide quantifiable efficacy endpoints. Numerous plant extracts have demonstrated statistically significant hepatoprotection in these models, lending support to ethnopharmacological claims.

Pharmacokinetic characterization of plant-derived hepatoprotective compounds presents a formidable challenge in translational research. Many bioactive phytochemicals, including curcumin and quercetin, exhibit poor oral bioavailability due to extensive first-pass metabolism, low aqueous solubility, and P-glycoprotein-mediated efflux [27]. Metabolic profiling studies have revealed rapid conjugation to glucuronide and sulfate forms that may retain reduced pharmacological activity relative to parent compounds. These pharmacokinetic limitations necessitate formulation innovation and are a primary driver of the gap between robust preclinical efficacy and equivocal clinical outcomes. The translation of preclinical findings to human studies is further complicated by species-specific differences in hepatic metabolism, the heterogeneity of liver disease etiology in clinical populations, and insufficient standardization of botanical extracts used in experimental studies [28].

6. Clinical Evidence: Efficacy, Safety, and Limitations

The clinical evidence supporting the hepatoprotective efficacy of medicinal plant preparations is growing but remains insufficiently robust for regulatory approval in most jurisdictions. Silymarin has the largest body of clinical data among hepatoprotective plants, with multiple randomized controlled trials evaluating its efficacy in alcoholic liver disease, NAFLD, viral hepatitis, and drug-induced hepatotoxicity [29]. Meta-analyses of silymarin trials in chronic liver disease generally indicate improvements in serum liver enzyme levels; however, clinical endpoints such as mortality, cirrhosis regression, and hepatocellular carcinoma incidence have not been significantly impacted in adequately powered studies.

Glycyrrhizin, administered intravenously as compound glycyrrhizin injection (SNMC), has demonstrated clinical efficacy in reducing hepatic inflammation in chronic hepatitis C patients in Japan, where it has received regulatory approval [30]. Andrographolide preparations have shown promising activity in clinical studies for hepatitis and acute liver injury in Asian populations, though rigorous Phase III trials are lacking. The safety profile of most medicinal plant hepatoprotectants is generally favorable, with hepatotoxicity from plant preparations themselves being a documented but comparatively rare adverse outcome. Notable exceptions include certain pyrrolizidine alkaloid-containing plants and kava extracts, which carry well-characterized hepatotoxic risks [31].

A critical limitation pervading the clinical literature is the substantial variability in botanical extract composition arising from differences in plant geography, cultivation conditions, harvesting time, and extraction methodology. Without standardized phytochemical fingerprinting and defined minimum content specifications for active constituents, inter-study comparability is severely compromised [32]. Furthermore, many published clinical studies suffer from small sample sizes, short study durations, absence of placebo control, and inadequate reporting of extract characterization, limiting their contribution to the evidentiary hierarchy required for drug approval.

7. Formulation Strategies and Novel Drug Delivery Systems

Recognition of the pharmacokinetic limitations inherent to many hepatoprotective phytochemicals has stimulated substantial research into novel drug delivery systems (NDDS) designed to improve bioavailability, facilitate hepatic targeting, and sustain therapeutic plasma concentrations. Nanoformulation technologies have emerged as the most extensively investigated approach, with lipid-based nanoparticles, polymeric nanoparticles, solid lipid nanoparticles, and self-emulsifying drug delivery systems demonstrating significantly enhanced curcumin, quercetin, and silymarin bioavailability in preclinical models [33].

Phospholipid complexes, particularly phytosomes, represent a commercially validated delivery strategy wherein plant polyphenols are complexed with phosphatidylcholine to improve lipophilicity and membrane permeability. Siliphos, a silybin-phosphatidylcholine complex, has demonstrated superior bioavailability compared to conventional silymarin preparations in both animal models and human pharmacokinetic studies [34]. Cyclodextrin inclusion complexes have similarly been employed to enhance the aqueous solubility of poorly water-soluble terpenoids including andrographolide. Hepatic targeting strategies employing ligand-decorated nanoparticles bearing asialoglycoprotein receptor (ASGPR) agonists represent an emerging frontier, exploiting the liver-specific expression of ASGPR to achieve preferential hepatocyte uptake and reduced systemic exposure [35]. Microencapsulation and co-crystallization technologies offer complementary approaches to sustained release and improved physicochemical stability of plant-derived drug candidates in solid oral dosage forms.

8. Regulatory, Safety, and Commercialization Challenges

The pathway from experimental hepatoprotective plant compound to approved pharmaceutical product is fraught with regulatory, scientific, and commercial challenges that collectively account for the paucity of licensed phytopharmaceuticals despite extensive preclinical evidence. Regulatory frameworks for botanical drugs differ substantially across jurisdictions, creating inconsistency in evidential requirements and approval pathways. The US Food and Drug Administration (FDA) Botanical Drug Guidance provides a framework for botanical IND and NDA applications but requires demonstration of consistent product identity, purity, strength, and composition that is technically demanding for complex plant extracts [36]. The European Medicines Agency (EMA) herbal medicinal product framework similarly requires evidence of well-established use or traditional use with plausibility of efficacy, and lacks specific guidance for NDA-equivalent marketing authorization based on pharmacological mechanism alone [37].

Standardization of plant-derived hepatoprotective products remains one of the most technically challenging aspects of their development as regulated medicines. Biological variability in phytochemical content across plant sources, seasonal variation, and processing differences necessitate sophisticated quality control infrastructure including high-performance liquid chromatography (HPLC), mass spectrometry, and nuclear magnetic resonance (NMR)-based fingerprinting [38]. Intellectual property challenges are also significant, as natural products cannot be patented in their native forms, reducing commercial incentive for large pharmaceutical investment in clinical development. Semi-synthetic derivatives and novel formulations provide patentable routes that are increasingly exploited to restore commercial viability to promising natural leads. Safety assessment of complex plant extracts is compounded by the potential for herb-drug interactions, particularly involving CYP450 enzyme inhibition or induction, which may alter the pharmacokinetics of co-administered pharmaceuticals [39].

9. Future Research Directions and Conclusions

The investigation of medicinal plants as sources of hepatoprotective drugs stands at a productive intersection of traditional knowledge, modern pharmacology, and translational medicine. Future research must prioritize several key areas to advance plant-derived hepatoprotectants from promising leads to clinically viable therapies. Rigorous phytochemical standardization and development of internationally harmonized quality benchmarks for hepatoprotective botanical preparations constitute foundational prerequisites for credible clinical research and regulatory submission [40].

Network pharmacology and systems biology approaches offer powerful tools for elucidating the multi-target mechanisms of complex plant extracts, potentially enabling rational combination strategies and identification of synergistic constituent pairs. High-throughput screening platforms integrating three-dimensional hepatic organoids and microphysiological liver-on-chip systems represent state-of-the-art *in vitro* models that more faithfully recapitulate human hepatic biology and may substantially improve the predictive validity of preclinical hepatoprotection studies. Adequately powered, randomized, double-blind clinical trials employing standardized botanical preparations with well-defined phytochemical profiles are urgently needed across key disease categories including NASH, ALD, and DILI. Biomarker discovery initiatives targeting non-invasive hepatic endpoints, including serum microRNA panels and metabolomic signatures of fibrosis regression, will facilitate meaningful efficacy assessment in clinical trials of hepatoprotective agents.

In conclusion, medicinal plants represent a scientifically credible and pharmacologically rich resource for hepatoprotective drug development. The mechanistic complexity and multi-target pharmacology of plant-derived bioactives offer potential advantages over single-target synthetic agents in diseases as pathogenically heterogeneous as chronic liver disease. However, realizing the therapeutic promise of these compounds demands systematic investment in standardization, mechanistic elucidation, pharmacokinetic optimization, and rigorous clinical evaluation. A collaborative framework involving ethnobotanists, pharmacologists, hepatologists, regulatory scientists, and pharmaceutical technologists will be essential to bridge the persistent gap between traditional wisdom and modern evidence-based hepatotherapy.

Figures



Fig 1: Mechanisms of Liver Injury and Points of Pharmacological Intervention by Medicinal Plant Compounds



Fig 2: Classification and Major Sources of Hepatoprotective Medicinal Plants and Their Active Constituents



Fig 3: Translational Pathway from Experimental Research to Clinical Development of Hepatoprotective Drugs Derived from Medicinal Plants

Tables

Table 1: Comparison of Selected Medicinal Plants, Their Active Compounds, and Mechanisms of Hepatoprotective Action

Medicinal Plant	Active Compound(s)	Mechanism of Action	Experimental Model(s)
Silybum marianum	Silybin, Silychristin	Antioxidant (Nrf2), anti-inflammatory (NF-kappaB), antifibrotic (TGF-beta1)	CCl4 rat, APAP mouse, HepG2
Curcuma longa	Curcumin	NF-kappaB inhibition, Nrf2 activation, SIRT1 modulation, antifibrotic	CCl4 rat, NASH mouse, LPS model
Andrographis paniculata	Andrographolide	NF-kappaB suppression, CYP450 modulation, anti-inflammatory	CCl4 rat, hepatitis model, *in vitro*
Glycyrrhiza glabra	Glycyrrhizin	Anti-inflammatory, immunomodulatory, TGF-beta inhibition	Chronic hepatitis C (clinical), CCl4 rat
Berberis vulgaris	Berberine	AMPK activation, lipid metabolism, antifibrotic, antioxidant	NAFLD mouse, HFD rat, HepG2
Picrorhiza kurroa	Picroside I, Kutkoside	Antioxidant, bile secretion, hepatocyte regeneration	CCl4 rat, APAP model
Phyllanthus niruri	Phyllanthin, Hypophyllanthin	Antiviral (HBV), anti-inflammatory, antioxidant	HBsAg cell line, HBV mouse model
Camellia sinensis	EGCG, Catechins	CYP2E1 inhibition, GST induction, antioxidant, lipid-lowering	ALD rat, NAFLD mouse, HepG2

Table 2: Advantages, Limitations, and Clinical Considerations of Plant-Based Hepatoprotective Therapies

Advantages	Limitations	Clinical Considerations
Multi-target pharmacological activity potentially addressing disease complexity	Variable phytochemical composition across batches and sources	Standardization of extracts is essential before clinical evaluation
Established ethnopharmacological safety profiles over centuries of traditional use	Poor bioavailability of key constituents (curcumin, quercetin)	Novel delivery systems required to achieve therapeutic plasma levels
Lower cost and wider geographic accessibility relative to synthetic biologics	Limited adequately powered Phase III clinical trial data	Regulatory approval requires rigorous randomized controlled trial evidence
Potential for synergistic constituent interactions within complex extracts	Risk of herb-drug pharmacokinetic interactions via CYP450 modulation	Full interaction profiling needed before co-prescription with hepatotropic drugs
Structural diversity providing diverse scaffold libraries for drug discovery	Intellectual property limitations on natural compounds reduce commercial investment	Semi-synthetic derivatives and formulation patents can enable commercial viability
Amenable to formulation optimization using modern NDDS technologies	Hepatotoxicity risk from specific plant classes (pyrrolizidine alkaloids, kava)	Pre-approval safety screening must exclude known hepatotoxic plant constituents

References

1. Trefts E, Gannon M, Wasserman DH. The liver. *Curr Biol.* 2017;27(21):R1147–R1151.
2. Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. *Clin Gastroenterol Hepatol.* 2020;18(12):2650–2666.
3. Bernal W, Wendon J. Acute liver failure. *N Engl J Med.* 2013;369(26):2525–2534.
4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. *J Hepatol.* 2022;77(3):807–855.
5. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology.* 2016;64(1):73–84.
6. Luber RP, Rentfrow PJ, Rabe C. Interest in complementary and alternative medicine among patients with liver disease. *J Viral Hepat.* 2018;25(4):406–411.
7. Subramaniam A, Shanmugam MK, Ong TH, Li F, Perumal E, Siveen KS, *et al*. Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3. *Br J Pharmacol.* 2013;170(4):807–821.
8. Govind P. Medicinal plants against liver diseases. *Int Res J Pharm.* 2011;2(5):115–121.
9. Sharma A, Chari S, Nagpal R, Kaur G. Phytotherapy in hepatic disorders: an update. *J Complement Integr Med.* 2018;15(1):1–12.
10. Cichoż-Lach H, Michalak A. Oxidative stress as a crucial factor in liver diseases. *World J Gastroenterol.* 2014;20(25):8082–8091.
11. Sies H, Berndt C, Jones DP. Oxidative stress. *Annu Rev Biochem.* 2017;86:715–748.
12. Hybertson BM, Gao B, Bose SK, McCord JM. Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation. *Mol Aspects Med.* 2011;32(4–6):234–246.
13. Jaeschke H, McGill MR, Ramachandran A. Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury. *Drug Metab Rev.* 2012;44(1):88–106.
14. Bataller R, Brenner DA. Liver fibrosis. *J Clin Invest.* 2005;115(2):209–218.
15. Dooley S, ten Dijke P. TGF-beta in progression of liver disease. *Cell Tissue Res.* 2012;347(1):245–256.
16. Calixto JB, Santos AR, Cechinel Filho V, Yunes RA. A review of the plants of the genus *Phyllanthus*. *Med Res Rev.* 1998;18(4):225–258.
17. Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. *Phytother Res.* 2010;24(10):1423–1432.
18. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. *AAPS J.* 2013;15(1):195–218.
19. Visen PK, Shukla B, Patnaik GK, Dhawan BN. Andrographolide protects rat hepatocytes against paracetamol-induced damage. *J Ethnopharmacol.* 1993;40(2):131–136.
20. Dong H, Wang N, Zhao L, Lu F. Berberine in the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. *Evid Based Complement Alternat Med.* 2012;2012:591654.
21. Valenzuela A, Aspillaga M, Vial S, Guerra R. Selectivity of silymarin on the increase of the glutathione content in different tissues of the rat. *Planta Med.* 1989;55(5):420–422.
22. Tan HY, Wang N, Lam W, Guo W, Feng Y, Cheng YC. Targeting the tumour microenvironment in hepatocellular carcinoma: the emerging role of phytochemicals. *Hepatol Int.* 2018;12(6):495–510.
23. Liang Y, Cheng Y, Lo CJ, Uetrecht AC, Lau CW, Huang Y. Green tea catechins augment the antioxidant defense of the liver. *Free Radic Res.* 2007;41(3):300–309.
24. Tsai JH, Liu JY, Wu TT, Ho PC, Huang CY, Shyu JC, *et al*. Effects of silymarin on the resolution of liver fibrosis induced by carbon tetrachloride in rats. *J Viral Hepat.* 2008;15(7):508–514.
25. Gomez-Lechon MJ, Lahoz A, Gombau L, Castell JV, Donato MT. *in vitro* evaluation of potential hepatotoxicity induced by drugs. *Curr Pharm Des.* 2010;16(17):1963–1977.
26. Constandinou C, Henderson N, Iredale JP. Modeling liver fibrosis in rodents. *Methods Mol Med.* 2005;117:237–250.
27. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. *Mol Pharm.* 2007;4(6):807–818.
28. Feinle-Bisset C, Azpiroz F. Dietary and lifestyle factors in functional dyspepsia. *Nat Rev Gastroenterol Hepatol.* 2013;10(3):150–157.
29. Mayer KE, Myers RP, Lee SS. Silymarin treatment of viral hepatitis: a systematic review. *J Viral Hepat.* 2005;12(6):559–567.

30. Ikeda K, Arase Y, Kobayashi M, Saitoh S, Someya T, Hosaka T, *et al*. A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C. *Cancer*. 2006;106(12):2700–2706.
31. Stickel F, Kessebohm K, Weimann R, Seitz HK. Review of liver injury associated with dietary supplements. *Liver Int.* 2011;31(5):595–605.
32. Bent S. Herbal medicine in the United States: review of efficacy, safety, and regulation. *J Gen Intern Med.* 2008;23(6):854–859.
33. Bonifacio BV, da Silva PB, Ramos MA, Negri KM, Bauab TM, Chorilli M. Nanotechnology-based drug delivery systems and herbal medicines. *Int J Nanomedicine.* 2014;9:1–15.
34. Kidd PM. Bioavailability and activity of phytosome complexes from botanical polyphenols. *Altern Med Rev.* 2009;14(3):226–246.
35. Huang Y, Hu L, Huang S, Xu W, Wan J. Curcumin-loaded galactosylated BSA nanoparticles as targeted drug delivery carriers inhibit hepatocellular carcinoma cell proliferation. *Int J Nanomedicine.* 2018;13:8309–8323.
36. US Food and Drug Administration. Botanical Drug Development: Guidance for Industry. Silver Spring: FDA; 2016.
37. European Medicines Agency. Guideline on quality of herbal medicinal products/traditional herbal medicinal products. London: EMA; 2020.
38. Rios JL, Waterman PG. A review of the pharmacology and toxicology of astragalus. *Phytother Res.* 1997;11(6):411–418.
39. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. *Drugs.* 2009;69(13):1777–1798.
40. World Health Organization. WHO guidelines on good herbal processing practices for herbal medicines. Geneva: WHO; 2018.